Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Negative-data clinical trials in lymphoma presented at ASH 2015

Jeremy Abramson • 5 Feb 2016
ASH 2015
Alisertib Bortezomib

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Dr Abramson focuses on the negative data presented at ASH 2015, in particular the Pyramid clinical trial that assessed the addition of bortezomib to R-CHOP in diffuse large cell lymphoma (DLBCL), the CALGB-50403 study of bortezomib following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL), and the Lumiere trial of alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL).

More from Jeremy Abramson

2:52
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson • 12 Dec 2022
2:05
Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson • 12 Dec 2022
3:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
Jeremy Abramson • 12 Dec 2022
2:46
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Jeremy Abramson • 12 Dec 2022
The content of VJHemOnc is intended for healthcare professionals